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Abstract
Background: This study aimed to evaluate the predictive values of hepatitis B e antigen (HBeAg) and hepatitis B
surface antigen (HBsAg) levels in 171 Chinese patients with chronic hepatitis B who received a 48-week course of
pegylated interferon alfa-2b therapy at 1.5 mcg/kg.
Methods: HBsAg, HBeAg, and hepatitis B virus (HBV) DNA levels were measured at baseline and weeks 12, 24, 48,
and 72. Clinical responses were defined as a combined response (CR, HBeAg seroconversion [sustained response,
SR] combined with HBV DNA level <2,000 IU/mL at week 72). The positive predictive value and negative predictive
value were calculated for HBsAg alone and/or combined with HBeAg and HBV DNA at weeks 12 and 24.
Results: Of 171 patients included, 58 (33.9 %) achieved a SR. Of patients who achieved a SR, 33 (56.9 %) achieved a CR.
Totally 19.3 % (33/171) patients achieved CR and 80.7 % (138/171) patients did not. Patients with HBsAg <1500 IU/mL
at week 12 had a 47.4 % chance of achieving an off-treatment SR and patients with a HBsAg decrease >1.5 logIU/mL
at week 12 had a 54.5 % chance. Patients with HBsAg >20,000 IU/mL at weeks 12 and 24 had a 93.8 and 100.0 %
chance, respectively, of not achieving a CR. An HBsAg level or changes at weeks 12 and 24, combined with HBeAg or
HBV DNA, increased the chance for a SR and CR.
Conclusions: On-treatment HBsAg quantification, alone or in combination with HBeAg or HBV DNA, predicted
off-treatment SR and CR after 48 weeks of PEG-IFNα-2b therapy, and thus, may guide clinicians in making a
therapeutic decision to continue or terminate the therapy.
Keywords: Chronic hepatitis B, Hepatitis B surface antigen (HBsAg), Peginterferon alfa-2b, Hepatitis B e antigen
(HBeAg), Combined response (CR)
Background
Chronic hepatitis B (CHB) affects more than 240 million
people worldwide (http://www.who.int/mediacentre/fact
sheets/fs204/en/, WHO Fact sheet, updated July 2016),
and in China alone, 30 million people are chronically in-
fected with an annual hepatitis B virus (HBV)-related
mortality of 300,000 [1, 2]. CHB progresses to liver
cirrhosis, liver failure, and even hepatocellular carcinoma
[2, 3]. Treatments to suppress HBV and slow the pro-
gression of liver inflammation are clinically important.
In general, HBsAg seroconversion (HBsAg loss followed
by the appearance of anti-HBs) is the ideal endpoint of
antiviral therapy, but it is rarely achieved. Induction of a
sustained off-therapy virological and biochemical response
in HBeAg-negative patients (either HBeAg-positive cases
at baseline with durable anti-HBe seroconversion or
HBeAg-negative cases from baseline) is a satisfactory end
point, because it has been shown to be associated with
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improved prognosis [4–9]. Pegylated interferon (PEG-
IFN) possesses both antiviral and immunomodulatory
effects and is one recommended therapy for CHB patients
[7–9]. PEG-IFN can produce a robust off-treatment re-
sponse in CHB patients [10–13]. However, only one-third
of treated patients show a response to PEG-IFN therapy
[14]. Thus, it is important to identify patients with a
high probability of achieving a satisfactory end point
or non-responders as early as possible for optimal
clinical management and treatment cost-effectiveness.
At present, several virological biomarkers such as
HBsAg, HBeAg, and HBV DNA levels are reported to
be predictive of the long-term response with PEG-
IFN treatment [15–21].
Prediction of off-treatment clinical responses by baseline
and on-treatment HBsAg levels as well as other HBV
biomarkers has been well established in PEG-IFN–treated
patients [20, 22–24]. However, these parameters have
negative prediction values (NPVs) as high as 97–100 %,
but relatively low positive prediction values (PPVs).
Whether combining different biomarkers can improve the
PPV has not been well studied. The present study aimed
to evaluate the predictive values of on-treatment HBsAg,
alone or combination with HBeAg and HBV DNA, for dif-
ferent clinical responses in Chinese HBeAg-positive CHB
patients treated with PEG-IFN alfa-2b.
Methods
Patients
This study was a post-hoc analysis of P05170, an Asian
regional, multicenter, randomized, controlled study
(NCT 00536263) evaluating the safety and efficacy of dif-
ferent dosing regimens in treatment-naïve Chinese pa-
tients with chronic hepatitis B [25]. Patients were eligible
for the P05170 study if they were between 18 and 65 years
of age, had CHB for at least 6 months, were positive for
HBeAg and HBsAg, had an alanine aminotransferase
(ALT) level between 2 and 10 times of upper limit of
normal (ULN) range, had HBV DNA levels exceeding
20,000 IU/mL, and had not received IFN therapy within
the previous 6 months. Patients were excluded if they
were co-infected with other types of hepatitis viruses (A,
C, D, or E) or HIV; had decompensated liver disease; had
previously received antiviral therapy within 6 months of
randomization; or had pre-existing co-morbidities consid-
ered unsuitable for enrollment. Patients visited an out-
patient hepatology clinic at each participating site for
clinical and HBV laboratory examinations every 12 weeks.
For the current study, patients who were initially
randomized to a 48-week course of PEG-IFN therapy
(1.5 μg/kg weekly) and had completed baseline, end of
treatment, and a 24-week follow-up clinical/laboratory
assessments (per protocol) were included in the ana-
lyses. A PEG-IFN dose of 1.5 μg/kg by 48 weeks was
recommended as a standard of care by published guide-
lines [5, 10]. It is reasonable to set up a prediction profile
of HBsAg/HBeAg levels using this PEG-IFN dosing
scheme to reflect clinical needs. Therefore, of 220 patients
randomized in the P05170 with available data, 171 pa-
tients met the criteria for inclusion in the current study.
This study was conducted in accordance with the guide-
lines of the Declaration of Helsinki and the principles of
Good Clinical Practice (ICH-E6). Written informed con-
sent according to standards of the local ethics committees
was obtained from all patients.
Laboratory measurement
All blood samples were stored in a central laboratory
(LabCorp, Beijing, China) under constant conditions for
samples containing hepatitis virus B (−80 °C). HBeAg
and HBsAg levels were measured at a central laboratory
in serum samples collected at baseline, every 12 weeks
during the treatment period, and during the follow-up in
the P05170 study. HBsAg levels were quantified using the
Elecsys® HBsAg II quantitative assay (electrochemilumines-
cence immunoassay, Roche Diagnostics, Indianapolis, IN)
by Modular Analytics E170 (Roche Diagnostics, (Roche
Diagnostics, Switzerland) with a range of 5–52,000 IU/ml
for up to a 400-fold-diluted sample. HBeAg levels were
quantified using the Elecsys® HBeAg II quantitative assay
(Modular Analytics E170 (Roche Diagnostics, (Roche Diag-
nostics, Switzerland) with a quantification lower limit of
5 IU/mL. HBV DNA quantification was performed using
Taqman-based polymerase chain reaction (PCR) assays
(COBAS® AmpliPrep/COBAS® TaqMan48, Roche Molecu-
lar Systems Inc.) with a lower limit of 6 IU/mL. HBV geno-
type was assessed using the INNO-LiPA line probe assay
(Innogenetics, Ghent, Belgium). ALT was measured locally
in accordance with standard laboratory procedures in
P05170 and was retrieved and presented as a multiple of
the ULN to minimize inter-laboratory assay bias.
Outcomes
In this study, sustained response (SR) was defined as
HBe seroconversion (HBeAg loss and positivity for
anti-HBeAg) at 24 weeks after the end of a 48-week
treatment. Combined response (CR) was defined as a
combination of SR and HBV DNA < 2000 IU/ml at
24 weeks after the end of a 48-week treatment. The cohort
was divided and presented by responder and non-
responder groups according to achievement of a CR.
Statistical analysis
All analyses were based on the responder versus non-
responder groups. Within- and between-group statistical
comparisons for HBsAg, HBeAg, and HBV DNA levels
during the treatment and at the end of study were
achieved by using mixed model repeated measures with
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no adjustment for covariates. Predictive accuracy was
analyzed and presented as PPV and NPV for SR and
CR, by setting cut-offs for HBsAg levels, alone or in
combination with HBeAg or the HBV DNA levels.
The area under the receiver operating characteristic
(ROC) curve (AUC) was assessed in terms of the predict-
ive strength of three different on-treatment parameters.
The patient’s baseline and on-treatment characteristics
were grouped and compared by CR.
Finally, logistic regression models (univariate and
multivariate analyses) were constructed to explore the
factors that were associated with the clinical response
as expressed by CR. All presented baseline and on-
treatment characteristics (on-treatment continuous
variables of HBsAg, HBeAg, and HBV DNA were not
included for the consideration of multicollinearity in
the model) were included in the univariate model,
and those with a p-value <0.1 were selected to enter
into multivariate model, where variables with p < 0.1
were retained by a hierarchical forward with switching
method.
All statistical analyses were performed using NCSS 10
software (NCSS, LLC, Kaysville, UT). All statistical tests
were two-sided and performed at the 0.05 level of sig-
nificance unless otherwise specified.
Results
Patient characteristics and clinical response rate
The off-treatment clinical response rates and the se-
lected baseline and on-treatment characteristics are
summarized in Table 1. Patients who achieved a CR had
significantly lower baseline HBsAg levels (p = 0.01) and a
shorter duration of HBV exposure, but higher baseline
ALT levels as presented by multiples of ULN (p = 0.05).
Patients who achieved a CR had significantly lower
HBsAg, HBeAg, and HBV DNA levels (all p values <0.05),
compared with those who did not, at on-treatment weeks
12 and 24. Similarly, proportions of patients who had a
significant decrease in HBsAg, HBeAg (>1.5 logIU/mL),
or HBV DNA (>2.0 logIU/mL) were significantly higher in
the groups of patients with a CR at weeks 12 and 24
(all p values <0.05).
Changes in on-treatment HBV DNA and HBV serological
markers
Changes in the quantified levels of HBV biomarkers
were analyzed and grouped by patients who achieved a
SR versus those who did not (Fig. 1). Overall, patients
who achieved a SR had significantly lower HBsAg levels
during the treatment and follow-up period than those
who did not (all p values < 0.01). In patients who had a
Table 1 Baseline and on-treatment characteristics of the study cohort
Characteristics Total CR (+) CR (−) p value
No. of patients 171 33 (19.3) 138 (80.7)
Age (years) 28.5 (7.9) 26.7 (7.6) 28.9 (7.9) 0.09
Gender (male) 130/171 (76.0) 24/33 (72.7) 106/138 (76.8) 0.62
BMI 22.2 (3.2) 22.0 (2.9) 22.2 (3.3) 0.71
Years of HBV Exposure 11.2 (9.3) 7.8 (5.5) 12.0 (9.8) 0.02
HBV Genotype
B 77 14 (42.4) 63 (45.7) 0.74
C 94 19 (57.6) 75 (54.3)
ALT (*ULN) 4.0 (1.9) 4.6 (2.3) 3.8 (1.8) 0.05
ALT > 5*ULN 35/171 (20.5) 10/33 (30.3) 25/138 (18.1) 0.12
HBsAg (Log10 IU/mL) 4.2 (0.6) 4.0 (0.6) 4.3 (0.6) 0.01
HBeAg (Log10 IU/mL) 2.6 (0.6) 2.4 (0.6) 2.6 (0.6) 0.09
HBV DNA (Log10 IU/mL) 7.8 (0.8) 7.7 (0.7) 7.8 (0.8) 0.44
On-treatment Quantifications, week 12
HBsAg decrease > 1.5Log 12/171 (7.0) 5/33 (15.2) 7/138 (5.1) 0.04
HBeAg decrease > 1.5Log 46/171 (26.9) 15/33 (45.5) 31/138 (22.5) 0.01
HBV DNA decrease > 2.0Log 51/171 (29.8) 18/33 (54.5) 33/138 (23.9) <0.01
On-treatment Quantifications, week 24
HBsAg decrease > 1.5Log 30/171 (17.5) 10/33 (30.3) 20/138 (14.5) 0.03
HBeAg decrease > 1.5Log 69/171 (40.4) 23/33 (69.7) 46/138 (33.3) <0.01
HBV DNA decrease > 2.0Log 77/171 (45.0) 24/33 (72.7) 53/138 (38.4) <0.01
Data are presented as Mean (SD) or n (%)
Combined response (CR) was defined as HBeAg seroconversion combined with HBV DNA level <2,000 IU/mL at 24 weeks after the end of treatment (week 72)
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SR, the HBsAg levels declined significantly during the
treatment period and the follow-up, compared with that
at baseline (all p values <0.01) and slightly rebounded at
follow-up week 72 compared with that at the end of
treatment (p = 0.33). On the contrary, in patients who
did not achieve a SR, HBsAg levels at week 72 were sig-
nificantly higher than those at week 48 (p = 0.02).
Prediction of CR by HBV DNA and HBV serological
biomarkers
The predictive values of on-treatment HBV biomarker
levels by cut-offs in absolute values and changes at weeks
12 and 24 for a CR are shown in Table 2. The PPVs and
NPVs of HBsAg quantifications by selected cut-offs (abso-
lute values) for the prediction of an SR and CR at weeks
12 and 24 are shown in Fig. 2. The probability of achieving
an off-treatment SR (PPV) was 47.4 % in patients who had
HBsAg less than 1500 IU/mL and 54.5 % in patients who
had an HBsAg decrease >1.5 logIU/mL at week 12. The
PPV for a SR was 54.5 % in patients who had an HBsAg
decrease >1.5 logIU/mL at week 12. In patients who had
an HBsAg >20,000 IU/mL at week 12, the likelihood of a
treatment failure to a CR was 93.8 % (NPV). The NPV for
a CR was 100.0 % in patients treated for 24 weeks but
who maintained HBsAg levels >20,000 IU/mL (ROC
AUC: 0.70, 0.71 at weeks 12 and 24, p values < 0.01, data
not shown).
HBeAg quantification gave a higher PPV for a SR at
weeks 12 and 24 than HBsAg (57.1 and 60.9 % vs 47.4
and 54.5 %, respectively). The PPV for a SR was 55.8
and 63.8 % in patients who had an HBeAg decrease >1.5
logIU/mL at weeks 12 and 24, respectively. The NPV
for a CR was 96.9 % in patients whose HBeAg decline
was <0.5 logIU/mL at week 24. Similarly, trends in
PPV analysis were seen in HBV DNA quantification.
The predictive accuracy of HBsAg quantification was
further explored by adding HBeAg as a combination
prediction scenario. The HBsAg decrease by a certain
amount (>1.5 logIU/mL) combined with HBeAg (>1.5
logIU/mL), at week 12 and 24, had an increased PPV for
a SR [71.4 (5/7) and 63.6 % (14/22) respectively, Fig. 3];
an HBsAg decrease >1.5 logIU/mL at week 12, com-
bined with HBeAg >1.5 logIU/mL or HBV DNA de-
crease >2.0 logIU/mL at week 12, had an increased PPV
for an off-treatment CR [57.1 (4/7) and 55.6 % (5/9) re-
spectively, Fig. 3]. When the HBsAg was decreased >1.5
logIU/mL along with an HBeAg >1.5 logIU/mL or an
HBV DNA decrease >2.0 logIU/mL, at week 24, the
PPVs for a CR were 40.9 (9/22) and 33.3 % (8/24), re-
spectively (Fig. 3).
Associated factors for predicting combined response
Exploratory analyses for identifying factors associated
with a CR were performed (Table 3). Univariate analysis
showed that the mean ALT at baseline (×ULN), mean
HBsAg at baseline (logIU/mL), mean HBeAg at baseline
(log IU/mL), on-treatment HBsAg decrease >1.5log,
HBeAg decrease >1.5log, and HBV DNA decrease >2.0log
at weeks 12 and 24 differed significantly between re-
sponders and non-responders groups (all p-values < 0.1),
and therefore, these variables were entered into a multi-
variate logistic regression model to evaluate their predict-
ive strength for a CR. Multivariate analysis suggested that
the baseline HBsAg level and a HBeAg decrease >1.5log
at week 24 were significantly associated with a CR
(both p-values <0.05).
Fig. 1 Mean changes (standard error) in HBsAg (a), HBeAg (b), and
HBV DNA (c) levels from baseline according to HBe seroconversion
response in HBeAg-positive CHB patients receiving PEG-IFN treat-
ment. *All p-values <0.01 for between-group comparisons at post-
baseline time points weeks 12, 24, 48, and 72. p-values <0.01 for
within-group comparisons between week 72 and baseline or week 48
for responders who achieved HBe seroconversion
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Discussion
PEG IFN is one of the first-line treatment options for
HBeAg positive CHB. Using a randomized controlled
trial cohort with CHB treated with a dosing scheme
of 1.5 μg/kg PEG-IFN alfa-2b weekly for 48 weeks,
the predictive profiles of HBsAg alone and combined
with HBeAg and HBV DNA levels for the clinical re-
sponse were investigated. The response rates reported
in this paper were consistent with those reported pre-
viously and comparable to those achieved with other
pegylated interferon therapies including PEG IFN 2a
[24, 26, 27]. The PPVs were relatively lower for the
prediction of CR in HBeAg-positive CHB patients
treated by PEG-IFN. In combination with HBeAg or
HBV DNA with selected cut-offs, HBsAg at weeks 12
or 24 had increased PPVs for predicting an off-
treatment response. Moreover, HBsAg with a selected
cut-off (>20,000 IU/mL) exhibited a high NPV for CR
at weeks 12 and 24.
Currently, PEG IFN is the only treatment choice for
HBeAg-positive CHB patients to achieve a sustained off-
treatment response. However, the response rate was not
satisfactory, with only 30 % of patients achieving a SR,
and the rate was even lower for a CR [14]. Considering
the low response rate and potential cost and safety is-
sues, it would be clinically beneficial to identify patients
who are likely (or unlikely) to develop a desired clinical
outcome as early as possible. In the present study,
HBsAg, HBeAg, and HBV DNA levels in the clinical re-
sponders decreased significantly during treatment and
by 24 weeks after the end of treatment; whereas non-
responders had a moderate decline at the beginning of
treatment and experienced significant rebounding there-
after. These preliminary data were consistent with previ-
ous findings [19, 20, 24] and increase the potential for
discovering how to individualize PEG-IFN alfa-2b-based
therapy according to longitudinal on-treatment HBsAg
levels. Recent studies have shown that serum levels of
HBsAg are associated with the levels of intrahepatic co-
valently closed circular DNA (cccDNA), and thus, the
HBsAg level has been considered a marker for the pre-
diction of a clinical response [28, 29]. The predictive
value of the HBsAg level for a clinical response to
PEG-IFN therapies has been validated in CHB pa-
tients [30–32]. In the present study, we found HBsAg
quantification alone at week 12 or 24 did not produce
statistically convincing PPVs for an off-treatment
Table 2 Prediction of CR by HBV DNA and serological
biomarkers
CR (+) CR (−) PPV NPV
HBsAg Week 12
Up to 1500 IU/mL 13 25 34.2 -
1500 - 20000 IU/mL 17 68 20.0 -
Over 20000 IU/mL 3 45 - 93.8
Week 12 Change
Up to −1.5 log IU/mL 5 6 45.5 -
− 1.5 ~ −0.5 log IU/mL 14 37 27.5 -
Over −0.5 log IU/mL 14 95 - 87.2
Week 24
Up to 1500 IU/mL 15 42 26.3 -
1500 - 20000 IU/mL 18 64 22.0 -
Over 20000 IU/mL 0 32 - 100.0
Week 24 Change
Up to −1.5 log IU/mL 10 20 33.3 -
− 1.5 ~ −0.5 log IU/mL 11 44 20.0 -
Over −0.5 log IU/mL 12 74 - 86.0
HBeAg Week 12
Up to 10 IU/mL 19 37 33.9 -
10 - 100 IU/mL 5 31 13.9 -
Over 100 IU/mL 9 70 - 88.6
Week 12 Change
Up to −1.5 log IU/mL 15 31 32.6 -
− 1.5 ~ −0.5 log IU/mL 11 34 24.4 -
Over −0.5 log IU/mL 7 73 - 91.3
Week 24
Up to 10 IU/mL 24 53 31.2 -
10 - 100 IU/mL 4 24 14.3 -
Over 100 IU/mL 5 61 - 92.4
Week 24 Change
Up to −1.5 log IU/mL 23 46 33.3 -
− 1.5 ~ −0.5 log IU/mL 8 29 21.6 -
Over −0.5 log IU/mL 2 63 - 96.9
HBV DNA Week 12
Up to 20000 IU/mL 12 16 42.9 -
Over 20000 IU/mL 21 122 - 85.3
Week 12 Change
Up to −2.0 log IU/mL 18 33 35.3 -
Over −2.0 log IU/mL 15 105 - 87.5
Week 24
Up to 20000 IU/mL 19 32 37.3 -
Over 20000 IU/mL 14 106 - 88.3
Table 2 Prediction of CR by HBV DNA and serological
biomarkers (Continued)
Week 24 Change
Up to −2.0 log IU/mL 24 53 31.2 -
Over −2.0 log IU/mL 9 85 - 90.4
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clinical response. A high HBsAg level >20,000 IU/mL
at weeks 12 and 24 predicted 93.8 and 100.0 % likeli-
hoods of not achieving a CR. This suggested a stop-
ping rule to discontinue PEG-IFN treatment for
patients who have a high absolute value of HBsAg at
week 12 or 24. These data were consistent with those
of previous studies on PEG-IFN [24, 30, 31].
On-treatment HBeAg quantification or decline also
showed a high prediction value for a SR with PEG-IFN
treatment. Freid et al. reported that patients with high
Fig. 2 Flow chart for predictive values of on-treatment HBsAg at weeks 12 (a) and 24 (b) for SR and CR at week 72. Three groups were assigned
according to HBsAg levels (<1500, 1500–20000, and >20000 IU/ml), and the respective PPV or NPV to SR and CR are presented
Fig. 3 Combined predictive value of changes of HbsAg, HBeAg, and HBV DNA at weeks 12 and 24 for SR and CR at week 72 (end of follow-up,
EOF). SR, sustained response; CR, combined response
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levels of HBeAg (>100 PEIU/mL) at week 24 had a 96 %
probability of no response [21]. Ji et al. reported that
87.5 % of patients with an HBeAg decline >2 log
achieved undetectable HBV DNA levels and 75.0 % who
had a HBeAg decline >2log achieved HBeAg seroconver-
sion [33]. The HBV DNA level is always predictive of a
SR during CHB treatment. Gheorghiţa et al. reported
that an on-treatment HBV-DNA reduction of >2 log10
IU/ml with any decrease in the HBsAg level at week 12
has a PPV of 80 % for SR [19]. For practical consider-
ation, the predictive roles of HBeAg and HBV DNA
might be used for an adjuvant HBsAg. For patients with
low-to-moderate HBsAg readings at week 12 or 24, a
clinical decision in terms of treatment continuation may
be strengthened by measuring HBsAg in combination
with HBeAg or HBV DNA. A combination of HBsAg
and HBeAg or HBV DNA at weeks 12 and 24 had gener-
ally better PPVs for CR in comparison with HBsAg alone.
In particular, a combination prediction scenario did not
simultaneously increase NPVs. Considering NPVs accord-
ing to HBsAg alone, this algorithm gives clinicians clear-
cut information for making a decision regarding early
treatment discontinuation but suggests more careful eval-
uations are needed for maintenance of PEG-IFN antiviral
treatment when HBsAg levels in the early on-treatment
phase are low-to-moderate. However, these data must be
interpreted with caution due to the relatively small sample
size in analysis of PPVs for combination predictions and
the results were preliminary per se.
This post-hoc analysis is among the limited number of
studies analyzing and reporting predictive profiles of
HBsAg quantification alone and in combination with
HBeAg or HBV DNA to identify off-treatment clinical
responses in patients treated by PEG-IFN alfa-2b. The
analyzed patient cohort can represent the disease popu-
lation in China, where HBV prevalence is the highest
despite the effective use of HBV vaccines. However, sev-
eral limitations existed. The analyzed patients were not
part of a large sample size, which may weaken the statis-
tical interpretation of PPVs and NPVs for clinical prac-
tice. The study results for HBsAg in combination with
other markers, are preliminary and require verification
in patients treated with PEG-IFN alfa-2b. We identified
clinical and laboratory factors that were significantly as-
sociated with an off-treatment clinical response by con-
structing a multivariate analysis model. However, due to
the lack of internal or external validation, the results
must be considered solely preliminary.
Conclusion
In conclusion, quantified on-treatment HBsAg was a
strong predictor for an off-treatment CR in Chinese
Table 3 Univariate and multivariate modeling of baseline and selected on-treatment characteristics
Characteristics CR (+)
Univariate Multivariate
OR (95 % CI) p value OR (95 % CI) p value
Age 0.96 (0.91, 1.01) 0.14
Gender (Male) 0.81 (0.34, 1.91) 0.62
BMI 0.98 (0.87, 1.10) 0.72
HBV Genotype (B) 0.88 (0.41, 1.89) 0.74
ALT (*ULN) 1.19 (1.00, 1.43) 0.05
ALT > 5*ULN 1.97 (0.83, 4.64) 0.12
HBsAg (Log10 IU/mL) 0.41 (0.22, 0.79) 0.01 0.38 (0.19, 0.79) 0.01
HBeAg (Log10 IU/mL) 0.61 (0.34, 1.08) 0.09
HBV DNA (Log10 IU/mL) 0.83 (0.51, 1.33) 0.43
On-treatment Quantifications, week 12
HBsAg decrease > 1.5Log 3.34 (0.99, 11.30) 0.05 3.36 (0.90, 12.56) 0.07
HBeAg decrease > 1.5Log 2.88 (1.30, 6.36) 0.01
HBV DNA decrease > 2.0Log 3.82 (1.73, 8.40) <0.01
On-treatment Quantifications, week 24
HBsAg decrease > 1.5Log 2.57 (1.06, 6.19) 0.04
HBeAg decrease > 1.5Log 4.60 (2.02 10.47) <0.01 4.02 (1.72, 9.39) <0.01
HBV DNA decrease > 2.0Log 4.28 (1.85, 9.90) <0.01
All baseline and selected on-treatment characteristics were analyzed for CR (N = 171) by univariate analysis and were all entered into multivariate model where
variables with p < 0.1 were retained by Hierarchical Forward with Switching Method
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HBeAg positive CHB patients who had received 48 weeks
of PEG-IFN alfa-2b treatment. On-treatment HBsAg
quantifications, in combination with HBeAg or HBV
DNA, predicted an off-treatment SR and CR after
48 weeks of PEG-IFNα-2b therapy. HBsAg quantifica-
tion as early as 12 weeks, in combination with HBeAg or
HBV DNA, predicted an off-treatment CR after 48 weeks
of treatment. These on-treatment predictors may help
clinicians decide whether to continue PEG-IFN alfa-
2b-based therapy or switch to an alternative therapy
in Chinese patients.
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